High-throughput crystallographic fragment screening of Zika virus NS3 Helicase
Andre S Godoy,Nathalya C. M. R. Mesquita,Gabriela Dias Noske,Victor Oliveira Gawriljuk,Ryan M Lithgo,Blake H Balcomb,Jasmin Cara Aschenbrenner,Charles W.E. Tomlinson,Max Winokan,Jenke Scheen,Peter George Marples,Anu V. Chandran,Xiaomin Ni,Warren Thompson,Michael Fairhead,Daren Fearon,Lizbé Koekemoer,Mary-Ann Elvina Xavier,Martin Walsh,Glaucius Oliva,Frank von Delft
DOI: https://doi.org/10.1101/2024.04.27.591279
2024-04-29
Abstract:The Zika virus (ZIKV), discovered in Africa in 1947, swiftly spread across continents, causing significant concern due to its recent association with microcephaly in newborns and Guillain-Barré syndrome in adults. Despite a decrease in prevalence, the potential for a resurgence remains, necessitating urgent therapeutic interventions. Like other flaviviruses, ZIKV presents promising drug targets within its replication machinery, notably the NS3 helicase (NS3 ) protein, which plays critical roles in viral replication. However, a lack of structural information impedes the development of specific inhibitors targeting NS3 . Here we applied high-throughput crystallographic fragment screening on ZIKV NS3 , which yielded structures that reveal 3D binding poses of 46 fragments at multiple sites of the protein, including 11 unique fragments in the RNA-cleft site. These fragment structures provide templates for direct design of hit compounds and should thus assist the development of novel direct-acting antivirals against ZIKV and related flaviviruses, thus opening a promising avenue for combating future outbreaks.
Biophysics